Retatrutide + Cagrilintide common uses, half-life, side effects and more

Retatrutide + Cagrilintide is an investigational pairing used for weight loss. Retatrutide is a drug in development for obesity that acts on three metabolic hormone pathways at once. Cagrilintide is a long-acting version of the fullness hormone amylin. It is also in development for weight loss. People combine the two to suppress appetite more than either does alone and to break through a weight-loss plateau. Neither drug is approved for sale anywhere and there is no legitimate prescription supply. The FDA has named both as ineligible for use in compounded medicines. Sellers offer the pair as one premixed vial or as two separate vials of unapproved research-grade material.

• Weight loss and appetite suppression
• Breaking a weight-loss plateau on retatrutide or another GLP-1 drug
• Stronger early fullness than retatrutide gives on its own
• Community body-composition protocols built on weekly injections

Once weekly

Both drugs are injected subcutaneously once weekly and the pair is run continuously rather than cycled. Retatrutide is titrated from about 2 mg toward a 4 to 8 mg weekly maintenance range. Some users reach 12 mg. Cagrilintide is added later and escalated slowly on its own. It starts near 0.25 mg weekly and steps up over several weeks toward as much as 2.4 mg. Those amounts match the two drugs' separate trials. Sellers offer the pair as one premixed vial or as two separate vials. Premix ratios vary and there is no established standard. The most listed version is a 5:1 ratio of 12.5 mg retatrutide plus 2.5 mg cagrilintide in a 15 mg vial. Vials at 4:1 and 1:1 also sell. A 5:1 premix delivers cagrilintide equal to a fifth of the retatrutide drawn. A 4 mg retatrutide dose gives 0.8 mg cagrilintide and a 12 mg dose gives 2.4 mg. A 1:1 premix instead delivers as much cagrilintide as retatrutide and can push it past its highest studied dose. Separate vials let each drug titrate on its own schedule and are preferred while adjusting doses.

• Assembling the pair as two separate vials lets retatrutide and cagrilintide follow different titration schedules
• Retatrutide is usually established first over several weeks before cagrilintide is layered on
• Some users inject the two on different days of the week to keep side effects traceable to one drug

No combination pharmacokinetic study of retatrutide and cagrilintide exists. Retatrutide has a human terminal half-life of about 6 days. Cagrilintide has a reported human half-life of 159 to 195 hours. Both components clear slowly enough to support once-weekly dosing.

• Nausea, vomiting, diarrhea, or constipation that peak during dose increases
• Loss of appetite that can tip into under-eating or dehydration
• Injection-site redness, itching, bruising, or swelling
• Fatigue, dizziness, headache, or weakness during dose escalation
• Skin tingling, burning, or numbness from the retatrutide component that is usually mild
• Resting heart rate can rise during escalation with gallbladder problems or hair shedding seen less often

• Retatrutide

  2 to 12 mg per weekly subcutaneous injection after slow titration

• Cagrilintide

  0.25 mg start raised toward 2.4 mg per weekly subcutaneous injection

Retatrutide activates three receptors at once. Those are the GIP, GLP-1, and glucagon receptors. GLP-1 and GIP signaling raises glucose-dependent insulin release and lowers appetite. GLP-1 also slows gastric emptying. The glucagon signal adds energy expenditure and fat breakdown. Cagrilintide activates the amylin receptors and the calcitonin receptor with little preference between them. Its weight effect in people is explained mainly by stronger satiety and lower food intake. The pairing stacks retatrutide's incretin and glucagon action with cagrilintide's amylin satiety to hit several appetite systems at once. That rationale comes from the separate component trials and from the cagrilintide and semaglutide combination.

Direct evidence for the retatrutide and cagrilintide combination is very low. No human trial, animal study, or pharmacokinetic study of the two together was found. Retatrutide has phase 2 obesity and diabetes data and a running phase 3 program as a single agent. Cagrilintide has phase 2 monotherapy data and phase 3 data only when paired with semaglutide. The cagrilintide and semaglutide combination is the closest studied analog. It does not establish the dose, safety, or effect of cagrilintide with retatrutide because the incretin partner differs. Most cagrilintide safety and effect figures come from trials where semaglutide was also given. The premix ratios and the combined dosing schedules are vendor and community conventions rather than trial protocols.

• The FDA has named both retatrutide and cagrilintide as ineligible for use in compounded medicines and neither is an approved drug
• Both components fall under WADA section S0 as non-approved substances so tested athletes should treat the whole blend as prohibited
• Animal studies of cagrilintide found major fetal malformations near human exposure levels so the blend is unsafe in pregnancy, breastfeeding, or attempts to conceive
• Long-term salmon calcitonin treatment showed a small unexplained rise in overall cancer risk and cagrilintide acts on the same calcitonin receptor
• A history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, or gallbladder disease is a reason to avoid the retatrutide component without medical supervision
• A fixed-ratio premix locks cagrilintide to the retatrutide dose so it cannot be started low and raised slowly the way cagrilintide tolerability needs